Baxter makes the dialysis machines, IV pumps, and surgical tools that hospitals and home-care patients rely on daily—think of it as the plumbing and life-support gear behind modern medicine.
Money comes from selling medical devices and supplies across ~100 countries, with gross margins around 30% and a recent quarterly net profit of USD 0.13B—though annual results have swung to losses, so earnings are uneven.
Switching costs are high because hospitals train staff on Baxter's infusion pumps and dialysis systems, and its home-dialysis franchise is entrenched—but Fresenius Medical Care and DaVita compete hard in kidney care, and Becton Dickinson pressures the IV pump
Hold (sector percentile 34) — value B-, growth B, profitability C-, momentum B, revisions B. Updated daily, sector-relative, identical for every user.
Key events, in time order
Stock extends post-earnings rally, valuation recovers from distressed levels, though gains may slow
Motley Fool reports Q2 sales $2.96B (+5% YoY), raised FY guidance, stock +19% on week
Q1 2026 global sales from continuing operations totaled $2.7 billion, representing 3% year-over-year reported growth but 1% organic decline
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
